ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells from patient blood. The resulting liquid biopsy (simple blood test) provides a powerful tool to deliver personalized cancer care. ANGLE is currently developing its first diagnostic product in the area of ovarian cancer. The Parsortix system has CE Mark regulatory approval in Europe and an FDA approval process is underway in the US.
Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Driven by a passion for excellence and a relentless commitment to quality, we unlock opportunities that advance innovation and deliver on the promise of a healthier world.
MolecularMD develops and commercializes specialty diagnostics for oncology applications. MolecularMD integrates proven and innovative platform technologies with clinical assay design, validation, and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. Read more.
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.
Through innovative solutions, Ventana empowers anatomic pathologists and laboratory professionals to increase testing efficiency. Our intuitive, integrated slide staining and workflow management platforms optimize laboratory operations to minimize errors, support diagnosis, and inform treatment decisions for anatomic pathology professionals.
Diagnostic certainty for every patient is a critical first step in the fight against cancer.
Agilent’s Dako pathology solutions are designed to help hospitals and pathology laboratories around the world make fast and accurate diagnoses. This enables the most effective treatment decisions for cancer patients, ultimately improving patient care and enhancing survival rates.
Almac Diagnostics is a precision medicine company, focused on the discovery, development and commercialisation of complex diagnostic tests. The company, based in Craigavon, UK and Durham, USA has been in existence for over 15 years.
Our diagnostic experience spans oncology, immunology, CNS, and infective diseases.We offer clients a highly Customised CDx partnership approach with tailored solutions, utilising complex biology, to help you differentiate your drug in the marketplace.
Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.
Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with… Read More
Horizon Diagnostics, a business unit of Horizon Discovery Group plc, is a leading provider of genetically defined, human genomic reference standards, including FFPE cell line sections and purified genomic DNA. HDx™ Reference Standards offer a sustainable source of reference material to laboratories, proficiency schemes and manufacturers, providing an unprecedented level of control.